In NSCLC, where inflammation and immune modulation are predominant, recent studies demonstrate that restoring BMAL1 function could potentially reduce oxidative stress and support anti-tumor immunity, opening avenues for circadian-based therapies [44]. This evidence concerns the gene BMAL1 and non-small cell lung carcinoma.